217 related articles for article (PubMed ID: 10190231)
1. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
Revicki DA
Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence.
Revicki DA
Curr Opin Investig Drugs; 2001 Jan; 2(1):110-7. PubMed ID: 11527002
[TBL] [Abstract][Full Text] [Related]
3. Service use and costs of treating schizophrenia with atypical antipsychotics.
Lewis M; McCrone P; Frangou S
J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.
Zito JM
Psychiatr Clin North Am; 1998 Mar; 21(1):181-202. PubMed ID: 9551496
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluations of olanzapine and risperidone.
Shaw JW
Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
[No Abstract] [Full Text] [Related]
7. Olanzapine and risperidone.
Love RC; Kelly DL
Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
[No Abstract] [Full Text] [Related]
8. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():3-9. PubMed ID: 9766613
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
10. Risperidone versus other atypical antipsychotic medication for schizophrenia.
Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
[TBL] [Abstract][Full Text] [Related]
11. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
12. Cost evaluation of risperidone compared with olanzapine.
Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
14. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
Zhao Z
Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
[TBL] [Abstract][Full Text] [Related]
15. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Leslie DL; Rosenheck R
J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
[TBL] [Abstract][Full Text] [Related]
16. The new atypical antipsychotics: a review of pharmacoeconomic studies.
Revicki DA
Expert Opin Pharmacother; 2000 Jan; 1(2):249-60. PubMed ID: 11249546
[TBL] [Abstract][Full Text] [Related]
17. [Atypical antipsychotics].
Naber D
Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
[No Abstract] [Full Text] [Related]
18. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
Amin S
Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
[TBL] [Abstract][Full Text] [Related]
20. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
De Beauchamp I; Giraud-Baro E; Gury C
Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
[No Abstract] [Full Text] [Related]
[Next] [New Search]
